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ture between January 2006 and December 2011. Controls were matched with cases 
at a 4:1 ratio on the following characteristics: gender, age, geographic region, and 
date of first dispensing of a TZD or insulin prescription. We conducted conditional 
logistic regression analyses to estimate the odds ratios (ORs) of having a fracture 
associated with the use of insulin compared to TZD while controlling for other 
covariates. Results: There were 2,842 cases matched to 8,238 controls. The mean 
(standard deviation) age of the study subjects was 46.5 years (0.9) and 57.6% were 
women. Among cases, 32.8% used insulin and 67.2% used TZDs, and for controls 
30.3% used insulin and 69.7% used TZDs. The crude OR for insulin users compared 
with TZD was 1.14 (95% confidence interval [CI], 1.04-1.25). After adjustment for 
other antidiabetic drugs, comedication, and comorbidities, the OR was 1.28 (95% 
CI, 1.09-1.49). ConClusions: We found an association between use of insulin and 
fractures compared to TZDs in patients with COPD and DM. While further research 
is needed, clinicians and policy makers should assure that screening guidelines 
consider this relative risk in patients with COPD and DM.
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objeCtives: Prandial insulins are a key component in insulin treatment in type 1 
diabetes mellitus (T1DM) and many type 2 diabetes mellitus (T2DM) patients. The 
evidence supporting a choice between available insulin preparations is still limited. 
We performed a systematic review of clinical data comparing efficacy and safety 
of insulin aspart (IAsp) and regular human insulin (RHI) in both types of diabe-
tes. Methods: Randomized controlled trials (RCTs) directly comparing IAsp with 
RHI after ≥ 12 weeks of treatment in patients with either T1DM or T2DM receiving 
prandial insulin regimens were retrieved within systematic search of medical data-
bases (MEDLINE, EMBASE, Cochrane’s CENTRAL) carried out up to May 2013. Results 
from individual studies were meta-analyzed and presented as weighted mean dif-
ference (WMD) or relative risk (RR). Results: Of 16 RCTs considered relevant for 
the current review, 11 papers referred to T1DM and 5 were representative for T2DM 
patients. Pooled results for T1DM population demonstrated that IAsp as compared 
with RHI provided larger reduction of the HbA1c level (9 RCTs; WMD[95%CI]= -0.11% 
[-0.16, -0.05]) as well as better postprandial glucose level following breakfast (4 RCTs; 
WMD[95%CI]= -1.40mmol/L [-1.72, -1.07]), lunch (3 RCTs; WMD[95%CI]= -1.01mmol/L 
[-1.61, -0.41]) and dinner (4 RCTs; WMD[95%CI]= -0.89mmol/L [-1.19, -0.59]). The 
risk of nocturnal hypoglycemia was lower in T1DM patients treated with IAsp (4 
RCTs; RR= 0.76 [0.64, 0.91]), while no difference was observed for severe hypogly-
cemic events. In T2DM patients IAsp lead to a larger HbA1c reduction (5 RCTs; 
WMD[95%CI]= -0.22% [-0.39, -0.05]) and provided superior postprandial blood glucose 
control. The risk of hypoglycemia, either overall or severe events was comparable 
between arms. ConClusions: IAsp provided better glycemic control as compared 
with RHI in T1DM and T2DM in patients receiving prandial insulin regimen. T1DM 
patients treated with IAsp were less prone to develop nocturnal hypoglycemia, 
while both interventions presented comparable risk of severe hypoglycemic events.
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objeCtives: To support a German Federal Joint Committee (G-BA) submission, 
a systematic review and meta-analysis feasibility were conducted to assess the 
efficacy and safety of the GLP-1 receptor agonist exenatide against pre-defined 
comparators as required by the G-BA, for the management of patients with Type 2 
diabetes mellitus (T2DM). Both the short- (Byetta®) and long-acting (Bydureon®) 
exenatide formulations were eligible for inclusion. Methods: Database searches 
(accessed September 2013) were conducted to identify eligible randomised 
controlled trials (RCTs) that evaluated Byetta®/Bydureon® in one of the G-BA 
approved indications. In the absence of appropriate head-to-head studies, the fea-
sibility of conducting a robust meta-analysis was assessed for outcomes of inter-
est. Results: With regard to Byetta®, single head-to-head RCTs were identified for 
two G-BA required comparisons: Byetta®+metformin vs metformin+sulphonylurea 
(SU) and Byetta®+metformin+SU vs insulin+metformin. No head-to-head RCTs 
were identified that assessed Bydureon® vs G-BA comparators. However, two RCTs 
were identified which permitted an indirect comparison of Bydureon®+metformin 
vs metformin + SU via a common treatment (sitagliptin+metformin). Baseline 
patient characteristics (body weight 81–89 kg; HbA1C 7.5–8.6%; duration of diabetes 
5–7 years across treatment arms) and study duration (26-30 weeks) were compa-
rable between trials. Bucher indirect comparison results indicated that treatment 
with Bydureon®+metformin was associated with a significantly greater reduc-
tion in HbA1C (mean difference -0.53% [95% confidence interval (CI): -0.84, -0.22; 
p= 0.001]) and weight (mean difference -3.5kg [95% CI:-4.4, -2.6; p< 0.001]) and a 
significantly lower incidence of minor hypoglycaemia (odds ratio (OR) 0.03 [95% 
CI: < 0.00, 0.17; p< 0.001]) compared with metformin+SU. The incidence of adverse 
events (AEs) (OR 1.06 [95% CI: 0.63, 1.79 p= 0.821]) and serious AEs (OR 1.22 [95% 
CI: 0.26, 5.70; p= 0.800]) was similar. ConClusions: Indirect comparison results 
indicate that in patients with T2DM, treatment with Bydureon®+metformin is 
associated with significant efficacy benefits and a similar safety profile compared 
with metformin+SU.
researCh Poster Presentations – session v
Disease-sPeCifiC stuDies
DiaBetes/enDoCrine DisorDers – Clinical outcomes studies
PDB1
ComParison of insulin glargine versus nPh insulin treatment 
among Patients with tyPe 2 DiaBetes BaseD on review of CliniCal 
trial results
Lin J., Lingohr-Smith M.
Novosys Health, Flemington, NJ, USA
objeCtives: Basal insulin therapy is commonly initiated in type 2 diabetes (T2DM) 
patients with a long-acting insulin, such as insulin glargine or the intermediate-
acting insulin, NPH. In this study we evaluated the frequency of hypoglycemia 
associated with insulin glargine vs. NPH insulin treatment based on clinical trial 
results. Methods: A systematic search was conducted in PubMed to identify 
clinical trials (2000-2013) in which the efficacy and safety of insulin glargine and 
NPH insulin treatments were evaluated among patients with T2DM. The primary 
outcomes assessed in this review of clinical trial results were the frequencies of 
symptomatic and nocturnal hypoglycemia during trial periods. Of the 366 abstracts 
reviewed, 7 were of clinical trials with insulin glargine and NPH insulin treatment 
arms in which hypoglycemia frequency was reported. Results: A total of 1,389 
T2DM patients were treated with insulin glargine and 1,132 with NPH insulin. The 
frequency of symptomatic hypoglycemia was highly variable across the trials, rang-
ing from 35%-96% with insulin glargine and 41%-77% with NPH insulin, as was noc-
turnal hypoglycemia frequency, which ranged from 13%-31% with insulin glargine 
and 10%-40% with NPH insulin. Two of the 7 trials reported that the frequency of 
symptomatic hypoglycemia was significantly less among T2DM patients treated 
with insulin glargine vs. NPH insulin. Of the 5 trials reporting the frequency of 
nocturnal hypoglycemia 4 reported it was significantly less among T2DM patients 
treated with insulin glargine vs. NPH insulin. Differences in the change in HbA1c 
during trial periods were reported as non-significant in all studies, except for 2 
with morning insulin glargine arms. ConClusions: Based on clinical trial results 
insulin glargine and NPH insulin appear similar in glycemic efficacy, but treat-
ment with insulin glargine may be associated with less symptomatic and nocturnal 
hypoglycemia than treatment with NPH insulin. Additional studies are needed to 
confirm these findings.
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objeCtives: Health care providers managing older patients with type 2 diabetes 
mellitus (T2DM) face a complex milieu of medical conditions and comorbidities, 
which increase the risk of unintended treatment consequences. The objective of this 
study was to understand major factors associated with hypoglycemia-related hospi-
talizations among adults with T2DM with an emphasis on older patients. Methods: 
A large claims-based retrospective cohort study in the United States was undertaken 
on actively registered patients with a diagnosis of T2DM and at least one diabetes 
treatment prescription, which included an oral or insulin/injectable anti-diabetes 
therapy. The main outcomes assessed included hypoglycemia-related hospitaliza-
tion and readmission, frequency of comorbidities, and clinical outcomes. Results: 
Of patients with T2DM with hospitalization records (n= 887,182), 52.3% were male 
and 30.7% were aged ≥ 65 years. At baseline, the proportion of patients taking met-
formin was 52.4%, insulin 7.3%, and sulfonylurea 26.4%. Among those who experi-
enced a diabetes-related hospitalization, the incidence of hospitalization-related 
hypoglycemia in patients ≥ 65 years of age was greater than in patients < 65 years 
of age (0.59 compared to 0.16 per 1000 person years). Using boosted regression tree 
modeling, age (older vs. younger), sulfonylurea use, insulin use and renal disease 
were the variables most associated with predicting a hospitalization associated 
with hypoglycemia. Elderly patients prescribed both insulin and sulfonylurea were 
most likely to have hypoglycemia-related hospitalizations (odds ratio= 4.7; 95% CI 
3.7-6.1). ConClusions: Older patients using both insulin and sulfonylurea were 
the most likely to experience a hypoglycemia-related hospitalization in this study. 
Age, sulfonylurea use, insulin use, and renal disease were the top four influen-
tial variables to be associated with hypoglycemia-related hospitalization, while 
glucagon-like peptide and dipeptidyl peptidase-4 were less likely to be associated 
these events. More research is required to quantify the burden of these events 
given sulfonylurea and insulin are presently seen as a very effective and low cost 
treatment alternatives.
PDB3
insulin or thiazoliDineDione use anD fraCture risk in Patients with 
ChroniC oBstruCtive Pulmonary Disease anD DiaBetes mellitus
Ursan I.D., Lee W.J., Lee T.A.
University of Illinois at Chicago, Chicago, IL, USA
objeCtives: Tight control of diabetes mellitus (DM) with insulin has the poten-
tial to increase hypoglycemic episodes which may result in fall and fracture risk. 
Moreover, patients with chronic obstructive pulmonary disease (COPD) are at high 
risk of fractures which may put patients with combination COPD and diabetes are 
particular risk. Our goal was to compare the risk of fractures associated with insulin 
use compared to TZDs in patients with COPD and DM. Methods: We conducted 
a nested case-control study using the IMS LifeLink® Health Plan Claims database, 
including patients at least 45 years old with a diagnosis of COPD and DM that were 
new users of either a TZD or insulin. Cases were individuals that experienced a frac-
